Tempest Therapeutics Inc (TPST)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.64M
Last updated: Nov 17, 2026 at 11:06 AM ET
Tempest Therapeutics Inc (TPST) Earnings: Report Dates and Results
Tempest Therapeutics (TPST) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Tempest Therapeutics reported EPS of -$0.21, above the -$0.32 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TPST has an expected report date of Mar 29, 2027.
Earnings History
Of the 39 quarters below that had an estimate, TPST beat 23, missed 15 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2018, when EPS landed 80.49% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.21 | -$0.32 | -$0.32 - -$0.32 | +34.38% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2026 | N/A |
| Jun 30, 2026 | -$0.34 | -$0.30 | -$0.30 - -$0.30 | -13.33% | Miss | N/A | 1 | 0 up, 0 down | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$0.50 | -$0.28 | -$0.28 - -$0.28 | -79.96% | Miss | N/A | 1 | 0 up, 0 down | May 14, 2026 | N/A |
| Dec 31, 2025 | -$0.62 | -$0.62 | -$0.62 - -$0.62 | 0.00% | In line | N/A | 1 | 1 up, 0 down | Mar 31, 2026 | N/A |
| Sep 30, 2025 | -$0.79 | -$3.27 | -$3.27 - -$3.27 | +75.84% | Beat | N/A | 1 | 1 up, 0 down | Nov 5, 2025 | N/A |
| Jun 30, 2025 | -$2.07 | -$3.23 | -$3.23 - -$3.23 | +35.91% | Beat | N/A | 1 | 1 up, 0 down | Aug 11, 2025 | N/A |
| Mar 31, 2025 | -$3.16 | -$3.29 | -$4.42 - -$2.47 | +3.95% | Beat | N/A | 3 | 1 up, 1 down | May 13, 2025 | N/A |
| Dec 31, 2024 | -$0.31 | -$0.25 | -$0.30 - -$0.19 | -26.53% | Miss | N/A | 4 | 1 up, 0 down | Mar 27, 2025 | $486000 |
| Sep 30, 2024 | -$5.33 | -$4.58 | -$5.20 - -$4.03 | -16.38% | Miss | N/A | 5 | 0 up, 0 down | Nov 12, 2024 | N/A |
| Jun 30, 2024 | -$5.46 | -$5.33 | -$7.28 - -$4.29 | -2.44% | Miss | N/A | 5 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$4.68 | -$4.94 | -$6.24 - -$4.29 | +5.26% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$0.38 | -$0.39 | -$0.43 - -$0.32 | +2.56% | Beat | N/A | 5 | 0 up, 0 down | Mar 19, 2024 | N/A |
| Sep 30, 2023 | -$6.24 | -$7.19 | -$8.19 - -$6.89 | +13.21% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2023 | N/A |
| Jun 30, 2023 | -$7.02 | -$7.54 | -$8.32 - -$4.29 | +6.90% | Beat | N/A | 4 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$7.15 | -$8.54 | -$8.71 - -$7.80 | +16.28% | Beat | N/A | 4 | 0 up, 0 down | May 10, 2023 | N/A |
| Dec 31, 2022 | -$0.63 | -$0.76 | -$0.89 - -$0.68 | +17.11% | Beat | N/A | 4 | 0 up, 0 down | Mar 22, 2023 | N/A |
| Sep 30, 2022 | -$8.58 | -$9.88 | -$12.09 - -$9.10 | +13.16% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2022 | N/A |
| Jun 30, 2022 | -$10.27 | -$12.00 | N/A | +14.42% | Beat | N/A | N/A | 0 up, 0 down | Aug 15, 2022 | N/A |
| Mar 31, 2022 | -$1.18 | -$1.12 | -$1.18 - -$1.12 | -5.36% | Miss | N/A | 3 | 0 up, 1 down | May 13, 2022 | N/A |
| Dec 31, 2021 | -$7.93 | -$16.03 | -$16.51 - -$15.47 | +50.53% | Beat | N/A | 3 | N/A | Mar 29, 2022 | N/A |
| Sep 30, 2021 | -$15.73 | -$13.61 | -$14.56 - -$12.35 | -15.58% | Miss | N/A | 3 | N/A | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$13.69 | -$11.37 | -$12.22 - -$10.53 | -20.40% | Miss | N/A | 2 | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$6.60 | -$5.25 | N/A | -25.71% | Miss | N/A | N/A | N/A | May 13, 2021 | N/A |
| Dec 31, 2020 | -$5.85 | -$5.15 | N/A | -13.59% | Miss | N/A | N/A | N/A | Mar 29, 2021 | N/A |
| Sep 30, 2020 | -$5.10 | -$6.90 | N/A | +26.09% | Beat | N/A | N/A | N/A | Nov 9, 2020 | N/A |
| Jun 30, 2020 | -$8.40 | -$8.20 | N/A | -2.44% | Miss | N/A | N/A | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$9.75 | -$10.00 | N/A | +2.50% | Beat | N/A | N/A | N/A | May 8, 2020 | N/A |
| Dec 31, 2019 | -$13.05 | -$12.18 | N/A | -7.14% | Miss | N/A | N/A | N/A | Mar 11, 2020 | N/A |
| Sep 30, 2019 | -$13.05 | -$12.38 | N/A | -5.41% | Miss | N/A | N/A | N/A | Nov 13, 2019 | N/A |
| Jun 30, 2019 | -$11.10 | -$12.12 | N/A | +8.42% | Beat | N/A | N/A | N/A | Aug 12, 2019 | N/A |
| Mar 31, 2019 | -$11.70 | -$10.55 | N/A | -10.90% | Miss | N/A | N/A | N/A | May 15, 2019 | N/A |
| Dec 31, 2018 | -$12.30 | -$12.85 | N/A | +4.28% | Beat | N/A | N/A | N/A | Mar 29, 2019 | N/A |
| Sep 30, 2018 | -$0.79 | -$4.05 | N/A | +80.49% | Beat | N/A | N/A | N/A | Nov 9, 2018 | N/A |
| Jun 30, 2018 | -$3.30 | -$4.05 | N/A | +18.48% | Beat | N/A | N/A | N/A | Aug 9, 2018 | N/A |
| Mar 31, 2018 | -$3.15 | -$0.28 | N/A | N/A | N/A | N/A | N/A | N/A | May 3, 2018 | N/A |
| Dec 31, 2017 | -$54.00 | -$61.95 | N/A | +12.83% | Beat | N/A | N/A | N/A | Mar 15, 2018 | N/A |
| Sep 30, 2017 | -$58.50 | -$89.78 | N/A | +34.84% | Beat | N/A | N/A | N/A | Nov 2, 2017 | $56000 |
| Jun 30, 2017 | -$114.75 | -$94.33 | N/A | -21.65% | Miss | N/A | N/A | N/A | Aug 3, 2017 | $84000 |
| Mar 31, 2017 | -$85.50 | -$95.96 | N/A | +10.90% | Beat | N/A | N/A | N/A | May 9, 2017 | $63000 |
| Dec 31, 2016 | -$110.25 | -$129.94 | N/A | +15.15% | Beat | N/A | N/A | N/A | Mar 2, 2017 | $121000 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$6.64, after -$15.78 the year before. It was -$551.25 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$6.64 | N/A |
| Dec 31, 2024 | -$15.78 | N/A |
| Dec 31, 2023 | -$20.79 | N/A |
| Dec 31, 2022 | -$20.66 | N/A |
| Dec 31, 2021 | -$43.95 | N/A |
| Dec 31, 2020 | -$29.10 | N/A |
| Dec 31, 2019 | -$48.90 | N/A |
| Dec 31, 2018 | -$19.54 | N/A |
| Dec 31, 2017 | -$312.75 | N/A |
| Dec 31, 2016 | -$551.25 | N/A |
Frequently Asked Questions About TPST
When is Tempest Therapeutics's next earnings date?
Tempest Therapeutics's next earnings report is expected for Mar 29, 2027.
Did TPST beat earnings estimates last quarter?
Yes. Tempest Therapeutics reported EPS of -$0.21 for the quarter ended Sep 30, 2026, above the -$0.32 estimate, a 34.38% surprise.
What EPS do analysts expect from TPST next quarter?
The consensus EPS estimate for Tempest Therapeutics for the quarter ending Dec 31, 2026 is -$0.30 from 3 analysts.
How often does TPST beat earnings estimates?
Tempest Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +3.78%.
TPST pages: Overview, Earnings, Forecast, Financials, Competitors